Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-0524A in primary hypercholesterolemia or mixed hyperlipidemia
2005-005093-70Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Nov 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of laropiprant + niacin, niacin and laropiprant in hypercholesterolemia and combined dyslipidaemia (3 arms), sponsored by Merck & Co. Primary endpoints: Plasma lipid and lipoprotein assessments, Flushing symptom severity and 1 more. Started Nov 2005; status: completed.
02
Drugs
laropiprant + niacinniacinlaropiprant
03
Conditions
hypercholesterolemiacombined dyslipidaemia
Beyond the preview
Go deeper on 2005-005093-70.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-005093-70.